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1  | INTRODUC TION
Dentine hypersensitivity (DH) is defined as ‘pain derived from ex‐
posed dentine in response to chemical, thermal, tactile or osmotic 
stimuli’ (Addy, 1990). DH occurs when dentine tubules are patent 
following dentine exposure, most frequently from gingival recession 
or enamel wear (Rimondini, Baroni, & Carrassi, 1995; West, Lussi, 
Seong, & Hellwig, 2013), and stimuli cause fluid movement within 
tubules leading to pulpal nerve excitation and subsequent pain 
(Brännström, 1963). Dentine hypersensitivity can negatively impact 
oral health‐related quality of life due to frequent pain insults (Gibson 
et al., 2010).
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Abstract
Aim: To	evaluate	effects	of	a	0.454%	stannous	fluoride	test	toothpaste	on	dentine	
hypersensitivity (DH) applied by fingertip, then 3 days’ brushing, versus a sodium 
monofluorophosphate‐based control. 
Materials and Methods: In three randomized clinical studies, DH was assessed using 
evaporative	 (Schiff	 scale)	 and	 tactile	 (Yeaple	 probe)	 stimuli.	 Participants	 applied	
toothpaste to two sensitive teeth by fingertip (60 s each); DH was re‐assessed, prior 
to brushing. Test treatment participants brushed their sensitive teeth, with all par‐
ticipants	then	brushing	all	teeth	for	≥60	s,	twice	daily	for	3	days.	DH	was	re‐assessed.	
Data were analysed by study and then pooled.
Results: In two studies, test treatment significantly reduced DH versus control treat‐
ment after fingertip application and 3 days’ brushing (both measures). In one study, 
both treatments significantly reduced DH without between‐treatment differences. 
Mean	 Schiff	 differences	 (95%	 confidence	 intervals)	 for	 fingertip/3d	 were	 as	 fol‐
lows:	Study	1:	−0.09	(−0.280,	0.092)/	−0.18	(−0.442,	0.072);	Study	2:	−0.72	(−0.839,	
−0.610)/	−1.02	(−1.150,	−0.882);	and	Study	3:	−0.26	(−0.387,	−0.123)/	−0.92	(−1.055,	
−0.793).	 Pooled	 analysis	 indicated	 test	 treatment	 significantly	 reduced	DH	versus	
control (both timepoints, both measures). Toothpastes were generally well‐tolerated.
Conclusion: Studies indicated that single, fingertip application of a SnF2 toothpaste 
reduced DH versus a control. DH relief increased over 3 days.
K E Y W O R D S
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Dentine hypersensitivity treatment focuses on two approaches: 
occluding dentine tubules or blocking impulse transmission in den‐
tinal nerves. The former relies on ingredients that form solid deposits 
which occlude/partially occlude dentine tubules so external stimuli do 
not cause substantial shifts in fluid movement (Earl & Langford, 2013; 
Earl, Ward, & Langford, 2010). Such agents include strontium or stan‐
nous salts (Makin, 2013; Markowitz, 2009; Mason et al., 2010; West, 
Seong, & Davis, 2015), arginine plus insoluble calcium salts (Bae, Kim, 
& Myung, 2015; Hughes et al., 2010) or bioglasses (Gendreau, Barlow, 
&	Mason,	2011;	Pradeep	&	Sharma,	2010).	This	approach	has	potential	
to work from first application (Ayad et al., 2009; Creeth, Gallob, et al., 
2017; Creeth, Goyal, et al., 2017; Fu et al., 2010; He, Barker, Qaqish, & 
Sharma, 2011; He, Chang, et al., 2011; He, Cheng, Biesbrock, Chang, 
&	Sun,	2011;	Mason	et	al.,	2010;	Nathoo	et	al.,	2009;	Parkinson	et	
al., 2013; Sharma, Roy, Kakar, Greenspan, & Scott, 2011; West, 
Newcombe, et al., 2013). Blocking of impulse transmission has been 
achieved by potassium ions (Bae et al., 2015; Markowitz, 2009); how‐
ever, repeated administration appears to be required before symp‐
tomatic	relief	occurs	(West,	Seong,	&	Davies,	2014).
Directly applying an occluding desensitizing toothpaste to reduce 
DH can be achieved through focused brushing or fingertip application. 
In the former, sensitive teeth are brushed first, followed by whole‐
mouth brushing (Creeth, Gallob, et al., 2017; Creeth, Goyal, et al., 
2017; He, Barker, et al., 2011; He, Chang, et al., 2011; He, Cheng, et al., 
2011;	Parkinson	et	al.,	2013;	Sharma	et	al.,	2011).	In	the	latter,	tooth‐
paste is gently massaged into sensitive teeth (Ayad et al., 2009; Fu et 
al., 2010; Mason et al., 2010; Nathoo et al., 2009; Schiff et al., 2009; 
West, Newcombe, et al., 2013), a technique frequently recommended 
by oral healthcare professionals for immediate DH symptom relief.
Stannous ions, most commonly used in toothpastes as stannous 
fluoride (SnF2), have been demonstrated to occlude dentine tu‐
bules in vitro (Burnett, 2013; Burnett, Wilson, & Lucas, 2013; Earl 
& Langford, 2013; Khan & Wilson, 2017). SnF2 toothpaste formula‐
tions have been used for several decades (Makin, 2013; Schiff, He, 
Sagel, & Baker, 2006) and are widely accepted as an effective DH 
treatment (Bae et al., 2015; West et al., 2015). Short‐term studies 
(up to 3 days) have overall been positive for SnF2 toothpastes applied 
using the focused brushing technique, with many demonstrating 
clinical efficacy versus a control toothpaste (Creeth, Gallob, et al., 
2017; Creeth, Goyal, et al., 2017; He, Barker, et al., 2011; He, Chang, 
et	al.,	2011;	He,	Cheng,	et	al.,	2011;	Parkinson	et	al.,	2016;	Sharma	et	
al., 2011). However, some DH studies with a SnF2	(Parkinson	et	al.,	
2016)	or	stannous	chloride	 (Cepeda‐Bravo	et	al.,	2014)	toothpaste	
have not shown differences.
There appears to be no published assessment of DH relief from 
SnF2 toothpastes applied using a fingertip technique. The three 
clinical studies presented here addressed this question using an 
experimental SnF2 toothpaste incorporating an anhydrous base (to 
stabilize stannous ions against oxidation and hydrolysis) and the 
polyphosphate pentasodium triphosphate (to control stannous ions’ 
propensity to stain enamel (Addy, Moran, Griffiths, & Wills‐Wood, 
1985). The objective was to determine whether this formulation 
could provide rapid, effective, symptomatic DH relief when applied 
by the fingertip technique after a single application, and also after 
3 days’ twice‐daily application by focused brushing, compared to a 
conventional fluoride toothpaste. An exploratory, post hoc, pooled 
analysis was carried out combining all results to estimate overall ef‐
ficacy across the three studies.
2  | MATERIAL S AND METHODS
These randomized, examiner‐blind, two‐treatment arm, parallel 
design studies were stratified by maximum baseline Schiff sensi‐
tivity score. Study 1 was conducted at two centres of a UK clini‐
cal research facility; Studies 2 and 3 were conducted at a UK dental 
school. The third study was performed after the first two studies 
had been completed. All studies were conducted in accordance 
with the Declaration of Helsinki, approved by independent research 
ethics committees before initiation and registered at ClinicalTrials.
org:	 Study	 1	 (NCT02612064):	 North‐West	 Lancaster	 REC,	 #15/
NW/0784;	Study	2	(NCT02751450):	NRES	South	West—Exeter	REC,	
16/SW/0006;	and	Study	3	(NCT02924350):	NRES	West	Midlands—
South	Birmingham	REC,	16/WM/0407.
2.1 | Participants
Studies enrolled healthy participants aged 18–55 (Study 1) or 18–65 
(Studies 2/3) years with no clinically significant or relevant abnor‐
malities	on	oral	examination.	Participants	had	≥20	natural	teeth	and	
a self‐reported history of DH between 6 months and 10 years. At 
screening, eligible participants had at least two non‐adjacent acces‐
sible teeth (incisors, canines or premolars) with dentine exposure 
at the cervical margin, a Modified Gingival Index (MGI) (Lobene, 
Weatherford, Ross, Lamm, & Menaker, 1986) score of 0 adjacent to 
the test area, no mobility, and a positive response to a qualifying 
Clinical Relevance
Scientific rationale for study: Stannous fluoride (SnF2) tooth‐
pastes have been shown in long‐term studies to reduce 
dentine hypersensitivity (DH). This investigation explored 
whether a SnF2 toothpaste applied by two focused meth‐
ods—fingertip	application	alone	or	with	focused	brushing	
prior	to	whole‐mouth	brushing—could	reduce	DH	immedi‐
ately and after short‐term use.
Principal findings: Across the three studies, the evidence 
showed the SnF2 toothpaste applied directly by fingertip 
reduced DH after a single use and, when applied by fo‐
cused brushing, following 3 days’ use, versus a non‐sensi‐
tivity toothpaste.
Practical implications: When applied directly to affected 
teeth, toothpastes containing SnF2 can reduce DH imme‐
diately and with continued use.
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evaporative (air) assessment. At baseline (Day 0), eligible participants 
had a minimum of two accessible, non‐adjacent teeth with signs of 
DH,	determined	by	a	qualifying	tactile	stimulus	threshold	of	≤20	g	
and	a	Schiff	sensitivity	score	≥2	(Schiff	et	al.,	1994).
Exclusion criteria included pregnancy; breastfeeding; allergy/
intolerance to study materials; any chronic debilitating disease that 
could affect study outcome; xerostomia; medication affecting pain 
perception;	dental	prophylaxis	within	4	weeks,	vital	tooth	bleaching	
within 8 weeks or scaling within 3 months of screening; periodontal 
disease; dental implants (test teeth only for Study 3); full coverage 
restorations; orthodontic brackets; caries; and sensitive teeth not 
expected to respond to treatment with over‐the‐counter tooth‐
pastes. Study 2 participants were ineligible for Study 3.
2.2 | Procedures
At the screening visit, each participant provided written informed 
consent before their demographic characteristics, medical history 
and medication use were recorded. An oral soft tissue (OST) ex‐
amination	was	conducted.	Participants’	dentition	was	assessed	se‐
quentially for missing teeth and teeth excluded as per the criteria; 
evidence of dentine exposure; gingival health status (MGI); tooth 
mobility; sensitivity to an evaporative (air) stimulus (where a ‘yes’ re‐
sponse indicated sensitivity). Eligible participants were supplied with 
an acclimatization toothpaste (Signal®	Family	Protection,	Unilever)	
and toothbrush (Aquafresh® Clean Control [Everyday Clean], GSK 
Consumer	Healthcare)	 to	 use	 twice	 daily	 for	 4–8	weeks	 between	
screening and baseline visits (acclimatization period). First tooth‐
paste use was carried out under supervision.
Before subsequent study visits, participants refrained from 
brushing their teeth and using any other oral hygiene aids, and from 
taking	analgesics	for	≥8	hr,	 from	eating	and	drinking	for	≥4	hr	and	
from	excessive	alcohol	 consumption	 for	24	hr.	 Sips	of	water	were	
permitted, but not within 1 hr of the study visit. During the study, 
participants could not use any other dental products, apart from 
dental floss for impacted food removal, and refrained from any non‐
emergency dental treatment.
At the baseline visit (Day 0), ongoing eligibility was assessed, any 
adverse events and changes to concomitant medications were re‐
corded, and acclimatization toothpaste compliance was confirmed. 
Following an OST examination, sensitivity of eligible teeth identified 
at screening was evaluated. The examiner selected two non‐adja‐
cent teeth, designated ‘test teeth’, from those that met the qualifying 
sensitivity assessments to be evaluated throughout the study.
Eligible participants were randomized to one of two toothpastes 
according to a schedule provided by the study sponsor's biostatistics 
department. Randomization was stratified by test teeth maximum 
baseline Schiff sensitivity score (2/3). The test toothpaste contained 
0.454%	SnF2	(1,100	ppm	fluoride)	and	5%	pentasodium	triphosphate	
in an anhydrous glycerin‐based formulation. The control toothpaste 
contained	 0.76%	 sodium	 monofluorophosphate	 (1,000	 ppm	 fluo‐
ride) (Colgate®	 Cavity	 Protection;	Colgate‐Palmolive)	 in	 a	 conven‐
tional aqueous formulation. Study products were overwrapped to 
blind participants to identity. The dental examiner, study statistician, 
data management staff and other sponsor employees were blinded 
to toothpaste allocation.
To assess the effect of a single fingertip application of tooth‐
paste, participants (under supervision) applied a pea‐sized amount 
of assigned study product to their fingertip and gently rubbed the 
toothpaste onto exposed dentine at the cervical margin of one of the 
two test teeth for 60 s. They repeated the procedure on the other 
test tooth. No rinsing was permitted. DH was then measured using 
evaporative (air) and tactile stimuli.
Prior	 to	 leaving	 the	 study	 centre,	 participants	 brushed	 (under	
supervision) with their assigned toothpaste. Test group participants 
used a focused brushing technique where they first brushed each of 
the two test teeth with a full ribbon of toothpaste on the toothbrush 
and then brushed their whole mouth for at least 60 s. Control group 
participants brushed their whole mouth with a full ribbon of tooth‐
paste	in	their	usual	manner	for	at	least	60	s.	Participants	could	rinse	
with 5 ml tap water for up to 5 s. At home, participants followed their 
assigned brushing regimen for 3 days, twice daily and then returned to 
the study centre. Following confirmation of ongoing study compliance 
and an OST examination, final DH assessments were undertaken.
2.3 | Assessments
In accordance with consensus guidelines (Holland, Narhi, Addy, 
Gangarosa, & Orchardson, 1997), two independent, stimulus‐based 
clinical measures were used to assess DH. Firstly, a tactile stimulus was 
administered	using	a	constant‐pressure	(Yeaple)	probe	(Polson,	Caton,	
Yeaple, & Zander, 1980) to the exposed sensitive dentine. Testing 
began at 10 g of pressure and then increased in 10 g increments for 
each successive challenge until the tactile threshold was reached 
where the participant gave two consecutive ‘yes’ responses, indicating 
the stimulus caused pain/discomfort, at the same pressure setting. At 
baseline, a maximum force of 20 g was used. At subsequent visits, if no 
response was given by 80 g, the reading was recorded as >80 g.
After a minimum 5 min recovery period, evaporative sensitivity was 
assessed by directing air from 1 cm for 1 s from a dental air syringe onto 
the exposed dentine surface, with the test tooth surface isolated to pre‐
vent exposure of adjacent teeth or surrounding soft tissue. The exam‐
iner's assessment of the participant's response to the evaporative (air) 
stimulus was recorded using the Schiff sensitivity scale (0 = participant 
does not respond to air stimulus; 1 = participant responds to air stimulus 
but does not request discontinuation; 2 = participant responds to air 
stimulus and requests discontinuation or moves from stimulus; 3 = par‐
ticipant responds to air stimulus, considers stimulus to be painful and re‐
quests	discontinuation	of	the	stimulus)	(Schiff	et	al.,	1994).	For	logistical	
reasons, in Study 1, separate examiners performed the two assessments, 
and in Studies 2 and 3, the same examiner performed both assessments.
2.4 | Safety
Spontaneously reported adverse events (AEs) and OST examina‐
tion abnormalities were recorded from first use of acclimatization 
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toothpaste until 5 days after last use of study toothpaste. The investi‐
gator graded each AE (mild, moderate, severe) and assessed whether 
they were treatment‐related. Treatment‐emergent AEs (TEAEs) were 
reported for the safety population, which included all randomized 
participants.
2.5 | Data analysis
2.5.1 | Sample size determination
Based on outcomes from previous studies (Goyal, Sufi, Qaqish, & 
Creeth,	2017;	Parkinson	et	al.,	2016),	for	Studies	1	and	2,	sufficient	
participants were screened to ensure approximately 107 per group 
completed	the	study	to	give	80%	power	to	detect	a	mean	difference	
of 0.25 (standard deviation [SD]	0.6487)	between	treatment	groups	
in change from baseline in Schiff sensitivity score after 3 days' use 
using a two‐sided t test of significance level 0.05. This represents 
a potentially clinically meaningful difference. Study 3 was powered 
based on Studies 1 and 2 outcomes; sufficient participants were 
screened to ensure approximately 92 evaluable participants per 
group	completed	the	study	to	give	90%	power	to	detect	a	mean	be‐
tween‐treatment difference of 0.25 units in Schiff sensitivity score 
(SD 0.5198) after 3 days’ use.
2.5.2 | Efficacy analyses
All statistical analyses were conducted using SAS version 9.2 (SAS 
Institute Inc.).
2.5.3 | Individual study analysis
The primary objective was to investigate the ability of the test treat‐
ment to reduce DH as elicited by evaporative (air) stimulus after 
3 days' use, compared to the control treatment. Secondary objec‐
tives included this comparison after a tactile stimulus and compari‐
son between treatments with both efficacy measures after a single 
fingertip application. Efficacy endpoints were change from baseline 
(mean of the two selected test teeth) for each efficacy measure at 
each timepoint. Efficacy analyses were performed on the intent‐to‐
treat (ITT) population, defined as all randomized participants who 
provided at least one post‐baseline assessment of efficacy.
Change from baseline was evaluated by analysis of covariance 
(ANCOVA). For Study 1 Schiff sensitivity score data, treatment 
group and study site were factors and baseline Schiff sensitivity 
score was a covariate. For Study 1 tactile threshold data, treatment 
group, study site and baseline Schiff sensitivity score stratification 
value were factors with baseline tactile threshold as a covariate. 
Similar analyses were performed for Studies 2 and 3 without study 
site as a factor.
2.5.4 | Pooled analysis
As an exploratory, post hoc analysis, data from all three studies were 
pooled and analysed based on the individual study ITT populations. 
Change from baseline in Schiff sensitivity scores at each timepoint was 
analysed using an ANCOVA with factors for treatment and study with 
baseline (Schiff sensitivity score) as a covariate. Tactile threshold data 
F I G U R E  1  Participant	disposition	
throughout study
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were analysed similarly except baseline Schiff stratification score was 
included as a factor and the covariate was baseline tactile threshold. 
The	effects	of	age	(median	age	≤30	years/>30	years)	and	gender	(male/
female) were investigated by introducing these as factors in the model.
An experimental ‘responder’ analysis was performed on change 
in Schiff sensitivity score, whereby an individual with a Schiff sensi‐
tivity	score	reduction	of	≥1	was	considered	a	‘responder’,	otherwise	
a ‘non‐responder’. This was repeated for a Schiff sensitivity score re‐
duction	of	≥0.5.	Analyses	were	conducted	separately	for	each	time‐
point	using	logistic	regression	via	PROC	LOGISTIC.	Factors	were	the	
same as for the ANCOVA model.
3  | RESULTS
Details of participant study flow are shown in Figure 1. Treatment 
group demographic characteristics were similar across groups for the 
safety and ITT populations of all studies (Table 1). There were differ‐
ences in baseline Schiff score distribution and mean participant age 
between studies, with Study 1 having both the highest proportion of 
those with baseline Schiff score 3, and the highest mean age. Study 
times (first participant enrolled/last participant completed) were 
as	 follows:	 Study	1:	November	 2015/June	2016;	 Study	2:	 February	
2016/June	2016;	and	Study	3:	November	2016/March	2017.
3.1 | Efficacy
In Study 1, treatment efficacy was not influenced by study centre, so 
this interaction term was not included in the model.
In all studies, for Schiff sensitivity scores, both test and control 
groups showed a statistically significant decrease from baseline 
after both single fingertip application (‘immediate’ use) and 3 days' 
brushing (Table 2, Figure 2a). In Studies 2 and 3, at both timepoints, 
the test treatment reduced Schiff scores significantly more than did 
the control (Table 2). Differences at all timepoints were considered 
clinically relevant (above 0.25 units). However, differences in Schiff 
scores between test and control did not reach significance at either 
timepoint in Study 1.
There was a statistically significant increase from baseline in tac‐
tile threshold scores for both treatments in Studies 2 and 3 at both 
timepoints (Table 2, Figure 2b). For Study 1 tactile threshold data, 
evidence of departure from model assumptions meant a nonpara‐
metric van Elteren test was performed; differences from baseline 
were not significant. For Studies 2 and 3, the test treatment gave 
statistically significantly higher tactile threshold scores versus con‐
trol following both immediate and 3 days’ use. As for the Schiff data, 
there were no significant differences between treatments in Study 
1 (Table 2).
In all studies, for both treatments and measures, DH relief in‐
creased over time.
3.2 | Pooled analysis
The post hoc pooled analysis demonstrated a statistically signifi‐
cantly greater decrease in Schiff sensitivity score and increase in 
tactile threshold for the test versus control treatment after both a 
single fingertip application and 3 days' use (Table 3; Figure 3), with 
degree of difference increasing over time (both measures). Allowing 
for the between‐study differences in efficacy as a function of age or 
gender showed almost identical results (Figure 3), indicating these 
did not meaningfully influence overall outcome.
The	experimental	 responder	analysis	 (Table	4)	 found	that	after	
a single fingertip application, the odds ratio for likelihood of expe‐
riencing a decrease in Schiff sensitivity score of at least 1 for the 
TA B L E  1   Summary of baseline characteristics (safety population)
Characteristic
Study 1 Study 2 Study 3
Test
(n = 115)
Control
(n = 115)
Test
(n = 117)
Control
(n = 116)
Test
(n = 102)
Control
(n = 102)
Sex, n	(%)
Male 24	(20.9) 23 (20.0) 36 (30.8) 31 (26.7) 37 (36.3) 28 (27.5)
Female 91 (79.1) 92 (80.0) 81 (69.2) 85 (73.3) 65 (63.7) 74	(72.5)
Age, years
Mean (SD) 40.7	(8.62) 39.9 (9.18) 34.3	(12.92) 32.8 (11.52) 22.8 (6.61) 22.2 (5.12)
Range 20–55 18–55 18–64 18–64 18–55 18–51
Race, n	(%)
White 112	(97.4) 112	(97.4) 93 (79.5) 102 (87.9) 85 (83.3) 90 (88.2)
Black 2 (1.7) 0 4	(3.4) 3 (2.6) 5	(4.9) 4	(3.9)
Asian 1 (0.9) 1 (0.9) 20 (17.1) 8 (6.9) 11 (10.8) 5	(4.9)
Other 0 2 (1.7) 0 3 (2.6) 1 (1.0) 3 (2.9)
Schiff strata 2, n	(%) 12	(10.4) 11 (9.6) 98 (83.8) 98	(84.5) 75 (73.5) 76	(74.5)
Schiff strata 3, n	(%) 103 (89.6) 104	(90.4) 19 (16.2) 18 (15.5) 27 (26.5) 26 (25.5)
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test	group	versus	the	control	was	4.4.	The	equivalent	odds	ratio	for	
a 0.5‐point decrease was 3.2. After 3 days' use, odds ratios were 
8.7	and	4.8,	respectively.	Differences	were	statistically	significant	at	
both timepoints, for both Schiff‐score changes.
3.3 | Safety
No TEAE was considered treatment‐related. In Study 1, three 
test group participants reported four TEAEs; five control group 
TA B L E  2   Change from baseline and between‐treatment comparisons for change in Schiff sensitivity score and tactile threshold (intent‐
to‐treat population)
 Test Control Test versus controlc
Schiff sensitivity scorea
Study 1
Baseline 2.82 (0.031) 2.80 (0.031)  
Immediate −0.41	(−0.54,	−0.27)
p < .0001
−0.31	(−0.44,	−0.18)
p < .0001
−0.09	(−0.280,	0.092)
p = .3226
Day 3 −0.96	(−1.14,	−0.78)
p < .0001
−0.77	(−0.95,	−0.59)
p < .0001
−0.18	(−0.442,	0.072)
p = .1575
Study 2
Baseline 2.12 (0.028) 2.12 (0.028)  
Immediate −0.89	(−0.97,	−0.81)
p < .0001
−0.17	(−0.25,	−0.09)
p < .0001
−0.72	(−0.839,	−0.610)
p < .0001
Day 3 −1.40	(−1.49,	−1.30)
p < .0001
−0.38	(−0.48,	0.28)
p < .0001
−1.02	(−1.150,	−0.882)
p < .0001
Study 3
Baseline 2.18 (0.033) 2.18 (0.033)  
Immediate −0.63	(−0.73,	−0.54)
p < .0001
−0.38	(−0.47,	0.28)
p < .0001
−0.26	(−0.387,	−0.123)
p = .0002
Day 3 −1.37	(−1.46,	−1.28)
p < .0001
−0.45	(−0.54,	0.35)
p < .0001
−0.92	(−1.055,	−0.793)
p < .0001
Tactile threshold (g)b
Study 1
Baseline 10 (10, 20) 10 (10, 20)  
Immediate 0	(−5,	65)d 0	(−10,	40)d p = .3372
Day 3 10	(−10,	80)d 5	(−10,	80)d p = .3719
Study 2
Baseline 10.85 (0.229) 10.69 (0.193)  
Immediate 19.42	(17.16,	21.68)
p < .0001
3.74	(1.47,	6.01)
p	=	.0014
15.68	(12.476,	18.883)
p < .0001
Day 3 35.48	(32.40,	38.55)
p < .0001
6.55	(3.47,	9.62)
p < .0001
28.93	(24.576,	33.277)
p < .0001
Study 3
Baseline 12.35 (0.373) 11.76	(0.346)  
Immediate 15.19 (12.81, 17.56)
p < .0001
8.05	(5.67,	10.43)
p < .0001
7.14	(3.768,	10.506)
p < .0001
Day 3 32.87 (30.03, 35.71)
p < .0001
10.37	(7.50,	13.24)
p < .0001
22.50	(18.458,	26.541)
p < .0001
aBaseline	values	are	raw	mean	scores	(±	standard	error);	post‐baseline	values	are	adjusted	mean	changes	from	baseline	(±	95%	confidence	interval).	
bBaseline values are raw median scores (minimum, maximum) for Study 1, raw mean scores (± standard error) for Studies 2 and 3; post‐baseline values 
are	adjusted	median	change	from	baseline	scores	(minimum,	maximum)	for	Study	1,	adjusted	mean	change	from	baseline	scores	(±	95%	confidence	
interval) for Studies 2 and 3. 
cDifference	(95%	confidence)	p‐value from ANCOVA model: first‐named minus second‐named group. For Schiff sensitivity score, a negative differ‐
ence favours the first‐named group. For Study 1 tactile threshold, p‐value is from a van Elteren nonparametric test. For tactile threshold (Studies 2 
and 3 only), a positive difference favours the first‐named group. 
dThe analysis of the statistical significance of change from baseline in Tactile threshold was not performed for Study 1. 
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participants reported six TEAEs. Four TEAEs were oral, in two test 
group participants and one control group participant. All TEAEs 
were mild (none serious) and resolved by study end. In Study 2, two 
test group participants reported two TEAEs; three control group 
participants reported three TEAEs. None were oral; four were mild 
and resolved by study end, one severe TEAE (prostate cancer) led 
to participant withdrew. In Study 3, nine test group participants re‐
ported nine TEAEs (one oral) and 11 control group participants re‐
ported 11 TEAEs (none oral); all were mild (none serious). One TEAE 
led to participant withdrawal (nasopharyngitis), all but one TEAE 
(gastric haemorrhage) resolved by study end.
4  | DISCUSSION
This is the first known report of a SnF2‐based toothpaste reducing 
DH when applied directly by fingertip to hypersensitive teeth. This is 
important because it enables individuals with DH to achieve imme‐
diate relief using a gentle, controllable product‐application method. 
Using this technique, two of the three studies showed the experi‐
mental SnF2 toothpaste reduced DH after single application signifi‐
cantly more than the control toothpaste on both evaporative (air) 
and tactile assessments.
The post hoc pooled analysis of the three studies indicated that 
there were overall treatment differences, with the pooled benefit in 
Schiff score across the three studies of 0.36 units. This is considered 
clinically significant relief. A complementary perspective on the data 
was provided by the experimental responder analysis, which con‐
cluded the test group participants had an odds ratio of measurable 
DH relief several times higher than control group participants.
The fingertip application approach has been reported to be ef‐
fective in clinical studies for two occlusion technologies: strontium 
acetate and arginine‐calcium carbonate (Ayad et al., 2009; Fu et al., 
2010; Mason et al., 2010; Nathoo et al., 2009; Schiff et al., 2009). 
The current studies confirm that the test SnF2 toothpaste applied by 
fingertip can also provide immediate DH relief. The control tooth‐
paste was not designed for DH treatment; however, the reduction in 
DH scores suggests that this toothpaste base can also provide some 
relief when massaged onto sensitive dentine. It is likely that abrasive 
particles and thickening agents within the formulation lodge at least 
temporarily in the tubule openings (West, Addy, & Hughes, 1998). 
The massaging action itself may also provide some minor relief (Ayad 
et al., 2009).
The fingertip application was followed by 3 days' twice‐daily 
brushing to gauge efficacy in a more conventional oral hygiene 
regimen. The test group used a focused‐brushing technique on 
F I G U R E  2   Mean (± standard error) 
a) Schiff sensitivity scores and b) tactile 
threshold (intent‐to‐treat population). 
Data offset for clarity; BL, baseline; tactile 
threshold values range from 0 to 80 g
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the test teeth; those in the control group brushed without spe‐
cifically treating sensitive areas. This approach was taken to fol‐
low previous studies (He, Barker, et al., 2011; He, Chang, et al., 
2011; He, Cheng, et al., 2011; Sharma et al., 2011) on the premise 
that individuals follow manufacturers' instructions for a product. 
This treatment reduced DH relative to baseline after 3 days in all 
three studies, across both treatment groups. The post hoc pooled 
analysis showed DH relief was greater in the test group than the 
control, continuing to build over the 3 days to reach a Schiff score 
difference of 0.70, considered clinically significant relief. The ex‐
perimental responder analysis reflected this conclusion, indicat‐
ing a several‐fold higher odds ratio for experiencing relief among 
test group participants. This degree of effect is consistent with 
previous studies of this toothpaste when applied solely by tooth‐
brushing: benefits were demonstrated after first use, increasing 
after 3 days (Creeth, Gallob, et al., 2017; Creeth, Goyal, et al., 
2017).
The three different studies performed here gave a range of re‐
sults. The third study, performed after the first two (which gave con‐
trasting results), is helpful in reaching an overall conclusion regarding 
efficacy. Of potential relevance to the different results observed 
were differences in participant characteristics: in Study 1, almost 
all participants were in the higher Schiff stratum, while in Studies 2 
and 3, the majority were in the lower stratum. Study 3 participants 
were generally younger than in Study 2, who in turn were generally 
younger than in Study 1.
 Test (n = 334) Control (n = 333) Test versus controlb
Schiff sensitivity scorea
Immediate −0.65	(−0.71,	−0.58)
p <.0001
−0.28	(−0.34,	−0.22)
p <.0001
−0.36	(−0.45,	−0.28)
p <.0001
Day 3 −1.24	(−1.32,	−1.16)
p <.0001
−0.53	(−0.61,	−0.46)
p <.0001
−0.70	(−0.81,	−0.59)
p <.0001
Tactile threshold (g)a
Immediate 14.47	(13.07,	15.87)
p <.0001
5.41	(4.01,	6.81)
p <.0001
9.06	(7.08,	11.04)
p <.0001
Day 3 27.66 (25.69, 29.63)
p <.0001
9.85 (7.87, 11.83)
p <.0001
17.81 (15.01, 20.60)
p <.0001
aAdjusted	mean	change	from	baseline,	95%	confidence	intervals	and	p‐value from ANCOVA model 
with treatment and study as factors (and Schiff sensitivity score for tactile threshold) and baseline 
Schiff sensitivity score or tactile threshold, as appropriate, as covariate 
bNegative difference favours the test toothpaste for the Schiff sensitivity score; positive difference 
favours the test toothpaste for the tactile threshold score 
TA B L E  3   Exploratory pooled 
analysis of Schiff sensitivity and tactile 
threshold scores (post hoc, intent‐to‐treat 
population)
F I G U R E  3   Schiff sensitivity score 
and tactile threshold mean between‐
treatment	difference	and	95%	CIs	for	
each individual study and pooled analysis 
including age, gender and baseline score 
as factors (intent‐to‐treat population), 
immediately after fingertip application 
and on Day 3. In Study 1, mean and 
95%	CIs	from	ANCOVA,	p‐value from 
nonparametric analysis
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The difference in average baseline Schiff score between stud‐
ies is of particular interest, raising the question whether the lack of 
treatment difference observed in Study 1 is linked to the high pro‐
portion of participants with Schiff score 3 in that study. However, 
assessing the effect of baseline DH severity is confounded by the 
fact that this difference cannot be disentangled from other study‐
to‐study differences. The pooled analysis considered differences 
in baseline DH severity, as well as differences in age and gender, 
and found none of these factors meaningfully affected the overall 
outcome.
The questions raised by these population differences regard‐
ing their influence on the analysis cannot be fully answered with 
available information; however, the authors believe the conclusion 
from the pooled analysis, indicating that clear differences exist be‐
tween the effects of test and reference treatments, is appropriate.
To clarify whether baseline Schiff score influences the difference 
in efficacy between the test and control treatments, a further, sep‐
arate study would be required, with sufficient participants in each 
baseline Schiff score stratum to permit a valid analysis.
Other factors may explain differences in results between stud‐
ies. It is well known in pain studies that response to an inactive treat‐
ment can occur due to expectation of a treatment benefit (placebo 
effects) (Kirsch, 2013), to behavioural changes due to study partici‐
pation	(Hawthorne	effects)	(Benedetti,	Carlino,	&	Piedimonte,	2016),	
or to the intrinsically episodic nature of DH, which may peak then 
resolve	without	intervention	(West,	Addy,	Jackson,	&	Ridge,	1997).	
In addition, due to normal biological variation, between‐treatment 
differences shown in a single study are estimates that may be above 
or below the true difference. Although a range of control steps were 
taken to reduce their potential impact, including acclimatization and 
inclusion criteria specifying DH duration, all these factors could have 
influenced results.
In conclusion, the evidence from the three studies presented in 
this	report	shows	that	0.454%	SnF2 formulated into an anhydrous, 
polyphosphate‐containing base can reduce DH pain when applied 
once directly by fingertip to hypersensitive teeth, relative to a 
conventional fluoride toothpaste. DH relief increased over 3 days of 
twice‐daily brushing. This conclusion supports and extends previ‐
ous studies of such toothpastes (Creeth, Gallob, et al., 2017; Creeth, 
Goyal,	 et	 al.,	2017;	Parkinson	et	al.,	2013,	2016),	which,	 taken	 to‐
gether, demonstrate the experimental formulation's ability to pro‐
vide short‐ and long‐term DH reduction.
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